The role of synaptic activity in the regulation of amyloid beta levels in Alzheimer's disease

Neurobiology of Aging

Volumn 35, Issue 6, 2014, Pages 1217-1232

  Cheng, Xiaofang ^a   Wu, Jian ^a   Geng, Miao ^b   Xiong, Jiaxiang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Amyloid beta; Synaptic activity

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA SECRETASE; AMYLOID BETA PROTEIN; BETA ADRENERGIC RECEPTOR; CHOLINERGIC RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; LEPTIN RECEPTOR; METABOTROPIC RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OREXIN RECEPTOR; PROTEIN KINASE C; SEROTONIN RECEPTOR; ACTIVITY REGULATED CYTOSKELETAL-ASSOCIATED PROTEIN; AMYLOID PRECURSOR PROTEIN; CYTOSKELETON PROTEIN; GLUTAMATE RECEPTOR; NERVE PROTEIN; SECRETASE; SIGNAL PEPTIDE;

ACTION POTENTIAL; ALZHEIMER DISEASE; CATALYSIS; CYTOSKELETON; DISEASE COURSE; DOWN REGULATION; ELECTROENCEPHALOGRAPHY; ENDOCYTOSIS; ENTORHINAL CORTEX; ENZYME ACTIVITY; GENE PRODUCT; GENETIC TRANSCRIPTION; HUMAN; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MEMORY CONSOLIDATION; MICRODIALYSIS; MOLECULAR DYNAMICS; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROMUSCULAR SYNAPSE; NONHUMAN; PATHOGENESIS; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; SPATIAL MEMORY; SYNAPSE; SYNAPTIC TRANSMISSION; TEMPORAL LOBE EPILEPSY; UPREGULATION; ANIMAL; BRAIN; DRUG DEVELOPMENT; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; CYTOSKELETAL PROTEINS; DRUG DISCOVERY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; RECEPTORS, CHOLINERGIC; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPSES;

EID: 84903365339     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.11.021     Document Type: Review

References (219)

1. Adamantidis A.R., Zhang F., Aravanis A.M., Deisseroth K., de Lecea L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007, 450:420-424.
2. Adriaanse S.M., Sanz-Arigita E.J., Binnewijzend M.A., Ossenkoppele R., Tolboom N., van Assema D.M., Wink A.M., Boellaard R., Yaqub M., Windhorst A.D., van der Flier W.M., Scheltens P., Lammertsma A.A., Rombouts S.A., Barkhof F., van Berckel B.N. Amyloid and its association with default network integrity in Alzheimer's disease. Hum. Brain Mapp 2012.
3. Albasanz J.L., Dalfo E., Ferrer I., Martin M. Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer's disease and dementia with Lewy bodies correlates with stage of Alzheimer's-disease-related changes. Neurobiol. Dis. 2005, 20:685-693.
4. Anagnostaras S.G., Murphy G.G., Hamilton S.E., Mitchell S.L., Rahnama N.P., Nathanson N.M., Silva A.J. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat. Neurosci. 2003, 6:51-58.
5. Arendt T. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization. Neuroscience 2001, 102:723-765.
6. Arendt T., Bigl V., Arendt A., Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease. Acta Neuropathol. 1983, 61:101-108.
7. Arjona A.A., Pooler A.M., Lee R.K., Wurtman R.J. Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. Brain Res. 2002, 951:135-140.
8. Ashford J.W. APOE genotype effects on Alzheimer's disease onset and epidemiology. J.Mol. Neurosci. 2004, 23:157-165.
9. Ashford J.W., Soultanian N.S., Zhang S.X., Geddes J.W. Neuropil threads are collinear with MAP2 immunostaining in neuronal dendrites of Alzheimer brain. J.Neuropathol. Exp. Neurol. 1998, 57:972-978.
10. Aston-Jones G., Cohen J.D. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu. Rev. Neurosci. 2005, 28:403-450.
11. Barnes N.M., Sharp T. Areview of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
12. Ben-Ari Y. Excitatory actions of gaba during development: the nature of the nurture. Nat. Rev. Neurosci. 2002, 3:728-739.
13. Bero A.W., Yan P., Roh J.H., Cirrito J.R., Stewart F.R., Raichle M.E., Lee J.M., Holtzman D.M. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat. Neurosci. 2011, 14:750-756.
14. Berridge C.W., Waterhouse B.D. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res. Brain Res. Rev. 2003, 42:33-84.
15. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
16. Blin J., Baron J.C., Dubois B., Crouzel C., Fiorelli M., Attar-Levy D., Pillon B., Fournier D., Vidailhet M., Agid Y. Loss of brain 5-HT2 receptors in Alzheimer's disease. Invivo assessment with positron emission tomography and [18F]setoperone. Brain 1993, 116(Pt 3):497-510.
17. Bloomer W.A.C., VanDongen H.M.A., VanDongen A.M.J. Activity-regulated cytoskeleton-associated protein Arc/Arg3.1 binds to spectrin and associates with nuclear promyelocytic leukemia (PML) bodies. Brain Res. 2007, 1153:20-33.
18. Bonnavion P., de Lecea L. Hypocretins in the control of sleep and wakefulness. Curr. Neurol. Neurosci. Rep. 2010, 10:174-179.
19. Bordji K., Becerril-Ortega J., Nicole O., Buisson A. Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-β production. J.Neurosci. 2010, 30:15927-15942.
20. Bourgin P., Huitron-Resendiz S., Spier A.D., Fabre V., Morte B., Criado J.R., Sutcliffe J.G., Henriksen S.J., de Lecea L. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J.Neurosci. 2000, 20:7760-7765.
21. Brody D.L., Magnoni S., Schwetye K.E., Spinner M.L., Esparza T.J., Stocchetti N., Zipfel G.J., Holtzman D.M. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 2008, 321:1221-1224.
22. Brookmeyer R., Evans D.A., Hebert L., Langa K.M., Heeringa S.G., Plassman B.L., Kukull W.A. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement. 2011, 7:61-73.
23. Buckner R.L., Snyder A.Z., Shannon B.J., LaRossa G., Sachs R., Fotenos A.F., Sheline Y.I., Klunk W.E., Mathis C.A., Morris J.C., Mintun M.A. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J.Neurosci. 2005, 25:7709-7717.
24. Buhot M.C., Martin S., Segu L. Role of serotonin in memory impairment. Ann. Med. 2000, 32:210-221.
25. Burnet P.W., Eastwood S.L., Lacey K., Harrison P.J. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res. 1995, 676:157-168.
26. Busche M.A., Eichhoff G., Adelsberger H., Abramowski D., Wiederhold K.H., Haass C., Staufenbiel M., Konnerth A., Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 2008, 321:1686-1689.
27. Caccamo A., Oddo S., Billings L.M., Green K.N., Martinez-Coria H., Fisher A., LaFerla F.M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006, 49:671-682.
28. Cachard-Chastel M., Lezoualc'h F., Dewachter I., Delomenie C., Croes S., Devijver H., Langlois M., Van Leuven F., Sicsic S., Gardier A.M. 5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice. Br. J. Pharmacol. 2007, 150:883-892.
29. Carey R.M., Balcz B.A., Lopez-Coviella I., Slack B.E. Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein. BMC Cell Biol. 2005, 6:30.
30. Carter M.E., Brill J., Bonnavion P., Huguenard J.R., Huerta R., de Lecea L. Mechanism for hypocretin-mediated sleep-to-wake transitions. Proc. Natl. Acad. Sci. U.S.A 2012, 109:E2635-E2644.
31. Chen H.S., Pellegrini J.W., Aggarwal S.K., Lei S.Z., Warach S., Jensen F.E., Lipton S.A. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J.Neurosci. 1992, 12:4427-4436.
32. Cho S., Hu Y. Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Exp. Neurol. 2007, 203:274-278.
33. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Schoepp D.D., Paul S.M., Mennerick S., Holtzman D.M. Synaptic activity regulates interstitial fluid amyloid-beta levels invivo. Neuron 2005, 48:913-922.
34. Cirrito J.R., Kang J.E., Lee J., Stewart F.R., Verges D.K., Silverio L.M., Bu G., Mennerick S., Holtzman D.M. Endocytosis is required for synaptic activity-dependent release of amyloid-beta invivo. Neuron 2008, 58:42-51.
35. Cirrito J.R., Disabato B.M., Restivo J.L., Verges D.K., Goebel W.D., Sathyan A., Hayreh D., D'Angelo G., Benzinger T., Yoon H., Kim J., Morris J.C., Mintun M.A., Sheline Y.I. Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans. Proc. Natl. Acad. Sci. U.S.A 2011, 108:14968-14973.
36. Cisse M., Halabisky B., Harris J., Devidze N., Dubal D.B., Sun B., Orr A., Lotz G., Kim D.H., Hamto P., Ho K., Yu G.Q., Mucke L. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 2011, 469:47-52.
37. Coleman P.D., Yao P.J. Synaptic slaughter in Alzheimer's disease. Neurobiol. Aging 2003, 24:1023-1027.
38. Consolo S., Arnaboldi S., Giorgi S., Russi G., Ladinsky H. 5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex. Neuroreport 1994, 5:1230-1232.
39. Cooper N.R., Bradt B.M., O'Barr S., Yu J.X. Focal inflammation in the brain: role in Alzheimer's disease. Immunol. Res. 2000, 21:159-165.
40. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
41. Coulson E.J., Paliga K., Beyreuther K., Masters C.L. What the evolution of the amyloid protein precursor supergene family tells us about its function. Neurochem. Int. 2000, 36:175-184.
42. Davis A.A., Fritz J.J., Wess J., Lah J.J., Levey A.I. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology invitro and invivo. J.Neurosci. 2010, 30:4190-4196.
43. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., Fukuhara C., Battenberg E.L., Gautvik V.T., Bartlett F.S., Frankel W.N., van den Pol A.N., Bloom F.E., Gautvik K.M., Sutcliffe J.G. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U.S.A 1998, 95:322-327.
44. Dixon R.A., Kobilka B.K., Strader D.J., Benovic J.L., Dohlman H.G., Frielle T., Bolanowski M.A., Bennett C.D., Rands E., Diehl R.E., Mumford R.A., Slater E.E., Sigal I.S., Caron M.G., Lefkowitz R.J., Strader C.D. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 1986, 321:75-79.
45. Doherty G.H., Beccano-Kelly D., Yan S.D., Gunn-Moore F.J., Harvey J. Leptin prevents hippocampal synaptic disruption and neuronal cell death induced by amyloid beta. Neurobiol. Aging 2013, 34:226-237.
46. Emorine L.J., Marullo S., Briend-Sutren M.M., Patey G., Tate K., Delavier-Klutchko C., Strosberg A.D. Molecular characterization of the human beta 3-adrenergic receptor. Science 1989, 245:1118-1121.
47. Farber S.A., Nitsch R.M., Schulz J.G., Wurtman R.J. Regulated secretion of beta-amyloid precursor protein in rat brain. J.Neurosci. 1995, 15:7442-7451.
48. Farr S.A., Banks W.A., Morley J.E. Effects of leptin on memory processing. Peptides 2006, 27:1420-1425.
49. Fernandez-Martos C.M., Gonzalez P., Rodriguez F.J. Acute leptin treatment enhances functional recovery after spinal cord injury. PLoS One 2012, 7:e35594.
50. Ferraguti F., Baldani-Guerra B., Corsi M., Nakanishi S., Corti C. Activation of the extracellular signal-regulated kinase 2 by metabotropic glutamate receptors. Eur. J. Neurosci. 1999, 11:2073-2082.
51. Fewlass D.C., Noboa K., Pi-Sunyer F.X., Johnston J.M., Yan S.D., Tezapsidis N. Obesity-related leptin regulates Alzheimer's Abeta. FASEB J. 2004, 18:1870-1878.
52. Fodale V., Quattrone D., Trecroci C., Caminiti V., Santamaria L.B. Alzheimer's disease and anaesthesia: implications for the central cholinergic system. Br. J. Anaesth. 2006, 97:445-452.
53. Foley A.G., Murphy K.J., Hirst W.D., Gallagher H.C., Hagan J.J., Upton N., Walsh F.S., Regan C.M. The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology 2004, 29:93-100.
54. Frielle T., Collins S., Daniel K.W., Caron M.G., Lefkowitz R.J., Kobilka B.K. Cloning of the cDNA for the human beta 1-adrenergic receptor. Proc. Natl. Acad. Sci. U.S.A 1987, 84:7920-7924.
55. Fronczek R., van Geest S., Frolich M., Overeem S., Roelandse F.W., Lammers G.J., Swaab D.F. Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol. Aging 2012, 33:1642-1650.
56. Fryer J.D., Holtzman D.M. The bad seed in Alzheimer's disease. Neuron 2005, 47:167-168.
57. Fryer J.D., Simmons K., Parsadanian M., Bales K.R., Paul S.M., Sullivan P.M., Holtzman D.M. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J.Neurosci. 2005, 25:2803-2810.
58. Giovannelli L., Casamenti F., Scali C., Bartolini L., Pepeu G. Differential effects of amyloid peptides beta-(1-40) and beta-(25-35) injections into the rat nucleus basalis. Neuroscience 1995, 66:781-792.
59. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Roques P., Talbot C., Pericak-Vance M., Roses A., Williamson R., Rossor M., Owen M., Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706.
60. Gomez-Isla T., Price J.L., McKeel D.W., Morris J.C., Growdon J.H., Hyman B.T. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J.Neurosci. 1996, 16:4491-4500.
61. Grabrucker A.M., Schmeisser M.J., Udvardi P.T., Arons M., Schoen M., Woodling N.S., Andreasson K.I., Hof P.R., Buxbaum J.D., Garner C.C., Boeckers T.M. Amyloid beta protein-induced zinc sequestration leads to synaptic loss via dysregulation of the ProSAP2/Shank3 scaffold. Mol. Neurodegener. 2011, 6:65.
62. Graham A.J., Ray M.A., Perry E.K., Jaros E., Perry R.H., Volsen S.G., Bose S., Evans N., Lindstrom J., Court J.A. Differential nicotinic acetylcholine receptor subunit expression in the human hippocampus. J.Chem. Neuroanat. 2003, 25:97-113.
63. Grammas P., Roher A.E., Ball M.J. Increased accumulation of cAMP in cerebral microvessels in Alzheimer's disease. Neurobiol. Aging 1994, 15:113-116.
64. Greco S.J., Bryan K.J., Sarkar S., Zhu X., Smith M.A., Ashford J.W., Johnston J.M., Tezapsidis N., Casadesus G. Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J.Alzheimers Dis. 2010, 19:1155-1167.
65. Greco S.J., Sarkar S., Casadesus G., Zhu X., Smith M.A., Ashford J.W., Johnston J.M., Tezapsidis N. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells. Neurosci. Lett. 2009, 455:191-194.
66. Greco S.J., Sarkar S., Johnston J.M., Tezapsidis N. Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem. Biophys. Res. Commun. 2009, 380:98-104.
67. Greco S.J., Sarkar S., Johnston J.M., Zhu X., Su B., Casadesus G., Ashford J.W., Smith M.A., Tezapsidis N. Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells. Biochem. Biophys. Res. Commun. 2008, 376:536-541.
68. Griffin W.S., Sheng J.G., Royston M.C., Gentleman S.M., McKenzie J.E., Graham D.I., Roberts G.W., Mrak R.E. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 1998, 8:65-72.
69. Gu Z., Zhong P., Yan Z. Activation of muscarinic receptors inhibits beta-amyloid peptide-induced signaling in cortical slices. J.Biol. Chem. 2003, 278:17546-17556.
70. Gutwein P., Mechtersheimer S., Riedle S., Stoeck A., Gast D., Joumaa S., Zentgraf H., Fogel M., Altevogt D.P. ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB J. 2003, 17:292-294.
71. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 2010, 11:682-696.
72. Hardingham G.E., Fukunaga Y., Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 2002, 5:405-414.
73. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
74. Harris J.A., Devidze N., Verret L., Ho K., Halabisky B., Thwin M.T., Kim D., Hamto P., Lo I., Yu G.Q., Palop J.J., Masliah E., Mucke L. Transsynaptic progression of amyloid-beta-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron 2010, 68:428-441.
75. Hellstrom-Lindahl E., Court J., Keverne J., Svedberg M., Lee M., Marutle A., Thomas A., Perry E., Bednar I., Nordberg A. Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. Eur. J. Neurosci. 2004, 19:2703-2710.
76. Heyman A., Wilkinson W.E., Stafford J.A., Helms M.J., Sigmon A.H., Weinberg T. Alzheimer's disease: a study of epidemiological aspects. Ann. Neurol. 1984, 15:335-341.
77. Higgins G.A., Ballard T.M., Kew J.N., Richards J.G., Kemp J.A., Adam G., Woltering T., Nakanishi S., Mutel V. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology 2004, 46:907-917.
78. Ho L., Fukuchi K., Younkin S.G. The alternatively spliced Kunitz protease inhibitor domain alters amyloid beta protein precursor processing and amyloid beta protein production in cultured cells. J.Biol. Chem. 1996, 271:30929-30934.
79. Hoey S.E., Williams R.J., Perkinton M.S. Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production. J.Neurosci. 2009, 29:4442-4460.
80. Holden K.F., Lindquist K., Tylavsky F.A., Rosano C., Harris T.B., Yaffe K. Serum leptin level and cognition in the elderly: findings from the Health ABC Study. Neurobiol. Aging 2009, 30:1483-1489.
81. Holscher C. Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol. Dis. 1998, 5:129-141.
82. Hong S., Quintero-Monzon O., Ostaszewski B.L., Podlisny D.R., Cavanaugh W.T., Yang T., Holtzman D.M., Cirrito J.R., Selkoe D.J. Dynamic analysis of amyloid beta-protein in behaving mice reveals opposing changes in ISF versus parenchymal abeta during age-related plaque formation. J.Neurosci. 2011, 31:15861-15869.
83. Huang F., Chotiner J.K., Steward O. Actin polymerization and ERK phosphorylation are required for Arc/Arg3.1 mRNA targeting to activated synaptic sites on dendrites. J. Neurosci. 2007, 27:9054-9067.
84. Huxtable R.J. Physiological actions of taurine. Physiol. Rev. 1992, 72:101-163.
85. Igbavboa U., Johnson-Anuna L.N., Rossello X., Butterick T.A., Sun G.Y., Wood W.G. Amyloid beta-protein1-42 increases cAMP and apolipoprotein E levels which are inhibited by beta1 and beta2-adrenergic receptor antagonists in mouse primary astrocytes. Neuroscience 2006, 142:655-660.
86. Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wolfing H., Chieng B.C., Christie M.J., Napier I.A., Eckert A., Staufenbiel M., Hardeman E., Gotz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
87. Jicha G.A., Weaver C., Lane E., Vianna C., Kress Y., Rockwood J., Davies P. cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. J.Neurosci. 1999, 19:7486-7494.
88. Johnson J.D., Cortez V., Kennedy S.L., Foley T.E., Hanson H., Fleshner M. Role of central beta-adrenergic receptors in regulating proinflammatory cytokine responses to a peripheral bacterial challenge. Brain Behav. Immun. 2008, 22:1078-1086.
89. Johnson V.E., Stewart W., Smith D.H. Traumatic brain injury and amyloid-beta pathology: a link to Alzheimer's disease?. Nat. Rev. Neurosci. 2010, 11:361-370.
90. Kalaria R.N., Andorn A.C., Tabaton M., Whitehouse P.J., Harik S.I., Unnerstall J.R. Adrenergic receptors in aging and Alzheimer's disease: increased beta2-receptors in prefrontal cortex and hippocampus. J.Neurochem. 1989, 53:1772-1781.
91. Kam T.I., Song S., Gwon Y., Park H., Yan J.J., Im I., Choi J.W., Choi T.Y., Kim J., Song D.K., Takai T., Kim Y.C., Kim K.S., Choi S.Y., Choi S., Klein W.L., Yuan J., Jung Y.K. FcγRIIb mediates amyloid-beta neurotoxicity and memory impairment in Alzheimer's disease. J.Clin. Invest 2013, 123:2791-2802.
92. Kang J.E., Lim M.M., Bateman R.J., Lee J.J., Smyth L.P., Cirrito J.R., Fujiki N., Nishino S., Holtzman D.M. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009, 326:1005-1007.
93. Kelly M.P., Deadwyler S.A. Acquisition of a novel behavior induces higher levels of Arc mRNA than does overtrained performance. Neuroscience 2002, 110:617-626.
94. Khlistunova I., Biernat J., Wang Y., Pickhardt M., von Bergen M., Gazova Z., Mandelkow E., Mandelkow E.M. Inducible expression of tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J.Biol. Chem. 2006, 281:1205-1214.
95. Kihara T., Shimohama S., Urushitani M., Sawada H., Kimura J., Kume T., Maeda T., Akaike A. Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res. 1998, 792:331-334.
96. Kim J., Onstead L., Randle S., Price R., Smithson L., Zwizinski C., Dickson D.W., Golde T., McGowan E. Abeta40 inhibits amyloid deposition invivo. J.Neurosci. 2007, 27:627-633.
97. Kim S., Swaminathan S., Shen L., Risacher S.L., Nho K., Foroud T., Shaw L.M., Trojanowski J.Q., Potkin S.G., Huentelman M.J., Craig D.W., DeChairo B.M., Aisen P.S., Petersen R.C., Weiner M.W., Saykin A.J. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011, 76:69-79.
98. Kim S.H., Fraser P.E., Westaway D., St George-Hyslop P.H., Ehrlich M.E., Gandy S. Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid(beta)42 from isolated intact nerve terminals. J.Neurosci. 2010, 30:3870-3875.
99. Kim T., Vidal G.S., Djurisic M., William C.M., Birnbaum M.E., Garcia K.C., Hyman B.T., Shatz C.J. Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science 2013, 341:1399-1404.
100. Kong Y., Ruan L., Qian L., Liu X., Le Y. Norepinephrine promotes microglia to uptake and degrade amyloid beta peptide through upregulation of mouse formyl peptide receptor 2 and induction of insulin-degrading enzyme. J.Neurosci. 2010, 30:11848-11857.
101. Korb E., Finkbeiner S. Arc in synaptic plasticity: from gene to behavior. Trends Neurosci. 2011, 34:591-598.
102. Lai M.K., Tsang S.W., Alder J.T., Keene J., Hope T., Esiri M.M., Francis P.T., Chen C.P. Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. Psychopharmacology (Berl) 2005, 179:673-677.
103. Lammich S., Kojro E., Postina R., Gilbert S., Pfeiffer R., Jasionowski M., Haass C., Fahrenholz F. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. U.S.A 1999, 96:3922-3927.
104. Lancelot E., Beal M.F. Glutamate toxicity in chronic neurodegenerative disease. Prog. Brain Res. 1998, 116:331-347.
105. Lanctot K.L., Herrmann N., Mazzotta P., Khan L.R., Ingber N. GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J. Psychiatry 2004, 49:439-453.
106. Lauren J., Gimbel D.A., Nygaard H.B., Gilbert J.W., Strittmatter S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009, 457:1128-1132.
107. Lawrence J.J. Cholinergic control of GABA release: emerging parallels between neocortex and hippocampus. Trends Neurosci. 2008, 31:317-327.
108. Lee H.G., Ogawa O., Zhu X., O'Neill M.J., Petersen R.B., Castellani R.J., Ghanbari H., Perry G., Smith M.A. Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease. Acta Neuropathol. 2004, 107:365-371.
109. Lee H.G., Zhu X., Casadesus G., Pallas M., Camins A., O'Neill M.J., Nakanishi S., Perry G., Smith M.A. The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival. Brain Res. 2009, 1249:244-250.
110. Lee R.K., Araki W., Wurtman R.J. Stimulation of amyloid precursor protein synthesis by adrenergic receptors coupled to cAMP formation. Proc. Natl. Acad. Sci. U.S.A 1997, 94:5422-5426.
111. Lee R.K., Wurtman R.J. Metabotropic glutamate receptors increase amyloid precursor protein processing in astrocytes: inhibition by cyclic AMP. J.Neurochem. 1997, 68:1830-1835.
112. Lee R.K., Wurtman R.J., Cox A.J., Nitsch R.M. Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc. Natl. Acad. Sci. U.S.A 1995, 92:8083-8087.
113. Lesne S., Ali C., Gabriel C., Croci N., MacKenzie E.T., Glabe C.G., Plotkine M., Marchand-Verrecchia C., Vivien D., Buisson A. NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J.Neurosci. 2005, 25:9367-9377.
114. Leveille F., El Gaamouch F., Gouix E., Lecocq M., Lobner D., Nicole O., Buisson A. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J. 2008, 22:4258-4271.
115. Levey A.I. Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A 1996, 93:13541-13546.
116. Levey A.I., Kitt C.A., Simonds W.F., Price D.L., Brann M.R. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J.Neurosci. 1991, 11:3218-3226.
117. Li S., Jin M., Zhang D., Yang T., Koeglsperger T., Fu H., Selkoe D.J. Environmental novelty activates beta2-adrenergic signaling to prevent the impairment of hippocampal LTP by abeta oligomers. Neuron 2013, 77:929-941.
118. Li X.L., Aou S., Oomura Y., Hori N., Fukunaga K., Hori T. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 2002, 113:607-615.
119. Lieb W., Beiser A.S., Vasan R.S., Tan Z.S., Au R., Harris T.B., Roubenoff R., Auerbach S., DeCarli C., Wolf P.A., Seshadri S. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 2009, 302:2565-2572.
120. Limon A., Reyes-Ruiz J.M., Miledi R. GABAergic drugs and Alzheimer's disease. Future Med. Chem. 2011, 3:149-153.
121. Link W., Konietzko U., Kauselmann G., Krug M., Schwanke B., Frey U., Kuhl D. Somatodendritic expression of an immediate early gene is regulated by synaptic activity. Proc. Natl. Acad. Sci. U.S.A 1995, 92:5734-5738.
122. Lipton S.A. Pathologically activated therapeutics for neuroprotection. Nat. Rev. Neurosci. 2007, 8:803-808.
123. Louzada P.R., Paula Lima A.C., de Mello F.G., Ferreira S.T. Dual role of glutamatergic neurotransmission on amyloid beta(1-42) aggregation and neurotoxicity in embryonic avian retina. Neurosci. Lett. 2001, 301:59-63.
124. Louzada P.R., Paula Lima A.C., Mendonca-Silva D.L., Noel F., De Mello F.G., Ferreira S.T. Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders. FASEB J. 2004, 18:511-518.
125. Lu J.X., Qiang W., Yau W.M., Schwieters C.D., Meredith S.C., Tycko R. Molecular structure of beta-amyloid fibrils in Alzheimer's disease brain tissue. Cell 2013, 154:1257-1268.
126. Luchsinger J.A., Tang M.X., Stern Y., Shea S., Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am. J. Epidemiol. 2001, 154:635-641.
127. Lue L.F., Walker D.G., Brachova L., Beach T.G., Rogers J., Schmidt A.M., Stern D.M., Yan S.D. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol. 2001, 171:29-45.
128. Mackenzie I.R., Miller L.A. Senile plaques in temporal lobe epilepsy. Acta Neuropathol. 1994, 87:504-510.
129. Maguire M.E., Ross E.M., Gilman A.G. beta-Adrenergic receptor: ligand binding properties and the interaction with adenylyl cyclase. Adv. Cyclic Nucleotide Res. 1977, 8:1-83.
130. Marcello E., Gardoni F., Mauceri D., Romorini S., Jeromin A., Epis R., Borroni B., Cattabeni F., Sala C., Padovani A., Di Luca M. Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity. J.Neurosci. 2007, 27:1682-1691.
131. Marcello E., Saraceno C., Musardo S., Vara H., de la Fuente A.G., Pelucchi S., Di Marino D., Borroni B., Tramontano A., Perez-Otano I., Padovani A., Giustetto M., Gardoni F., Di Luca M. Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer's disease. J.Clin. Invest. 2013, 123:2523-2538.
132. Mattson M.P. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 1997, 77:1081-1132.
133. Mattson M.P., Cheng B., Culwell A.R., Esch F.S., Lieberburg I., Rydel R.E. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 1993, 10:243-254.
134. McCurry S.M., Logsdon R.G., Teri L., Gibbons L.E., Kukull W.A., Bowen J.D., McCormick W.C., Larson E.B. Characteristics of sleep disturbance in community-dwelling Alzheimer's disease patients. J.Geriatr. Psychiatry Neurol. 1999, 12:53-59.
135. Mesulam M.M. Aplasticity-based theory of the pathogenesis of Alzheimer's disease. Ann. N. Y Acad. Sci. 2000, 924:42-52.
136. Mitchell E.S., Neumaier J.F. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol. Ther. 2005, 108:320-333.
137. Mrak R.E., Griffin W.S. Glia and their cytokines in progression of neurodegeneration. Neurobiol. Aging 2005, 26:349-354.
138. Muller T., Meyer H.E., Egensperger R., Marcus K. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog. Neurobiol. 2008, 85:393-406.
139. Myers M.G., Cowley M.A., Munzberg H. Mechanisms of leptin action and leptin resistance. Annu. Rev. Physiol. 2008, 70:537-556.
140. Nelson R.L., Guo Z., Halagappa V.M., Pearson M., Gray A.J., Matsuoka Y., Brown M., Martin B., Iyun T., Maudsley S., Clark R.F., Mattson M.P. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp. Neurol. 2007, 205:166-176.
141. Ni Y., Zhao X., Bao G., Zou L., Teng L., Wang Z., Song M., Xiong J., Bai Y., Pei G. Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat. Med. 2006, 12:1390-1396.
142. Niedowicz D.M., Studzinski C.M., Weidner A.M., Platt T.L., Kingry K.N., Beckett T.L., Bruce-Keller A.J., Keller J.N., Murphy M.P. Leptin regulates amyloid beta production via the gamma-secretase complex. Biochim. Biophys. Acta 2013, 1832:439-444.
143. Nitsch R.M., Deng M., Growdon J.H., Wurtman R.J. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J.Biol. Chem. 1996, 271:4188-4194.
144. Nordberg A., Hellstrom-Lindahl E., Lee M., Johnson M., Mousavi M., Hall R., Perry E., Bednar I., Court J. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J.Neurochem. 2002, 81:655-658.
145. Obregon D., Hou H., Deng J., Giunta B., Tian J., Darlington D., Shahaduzzaman M., Zhu Y., Mori T., Mattson M.P., Tan J. Soluble amyloid precursor protein-alpha modulates beta-secretase activity and amyloid-beta generation. Nat. Commun. 2012, 3:777.
146. Oddo S., Vasilevko V., Caccamo A., Kitazawa M., Cribbs D.H., LaFerla F.M. Reduction of soluble abeta and tau, but not soluble abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J.Biol. Chem. 2006, 281:39413-39423.
147. Okuno H., Akashi K., Ishii Y., Yagishita-Kyo N., Suzuki K., Nonaka M., Kawashima T., Fujii H., Takemoto-Kimura S., Abe M., Natsume R., Chowdhury S., Sakimura K., Worley P.F., Bito H. Inverse synaptic tagging of inactive synapses via dynamic interaction of Arc/Arg3.1 with CaMKIIbeta. Cell 2012, 149:886-898.
148. Ono K., Hasegawa K., Yamada M., Naiki H. Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils invitro. Biol. Psychiatry 2002, 52:880-886.
149. Pakaski M., Bjelik A., Hugyecz M., Kasa P., Janka Z., Kalman J. Imipramine and citalopram facilitate amyloid precursor protein secretion invitro. Neurochem. Int. 2005, 47:190-195.
150. Palop J.J., Chin J., Bien-Ly N., Massaro C., Yeung B.Z., Yu G.-Q., Mucke L. Vulnerability of dentate granule cells to disruption of arc expression in human amyloid precursor protein transgenic mice. J.Neurosci. 2005, 25:9686-9693.
151. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G.-Q., Kreitzer A., Finkbeiner S., Noebels J.L., Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
152. Palop J.J., Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 2010, 13:812-818.
153. Park S., Park J.M., Kim S., Kim J.A., Shepherd J.D., Smith-Hicks C.L., Chowdhury S., Kaufmann W., Kuhl D., Ryazanov A.G., Huganir R.L., Linden D.J., Worley P.F. Elongation factor 2 and fragile X mental retardation protein control thedynamic translation of Arc/Arg3.1 essential for mGluR-LTD. Neuron 2008, 59:70-83.
154. Paula-Lima A.C., De Felice F.G., Brito-Moreira J., Ferreira S.T. Activation of GABA(A) receptors by taurine and muscimol blocks the neurotoxicity of beta-amyloid in rat hippocampal and cortical neurons. Neuropharmacology 2005, 49:1140-1148.
155. Pauszek M.E. Propranolol for treatment of agitation in senile dementia. Indiana Med. 1991, 84:16-17.
156. Phillips T., Barnes A., Scott S., Emson P., Rees S. Human metabotropic glutamate receptor 2 couples to the MAP kinase cascade in chinese hamster ovary cells. Neuroreport 1998, 9:2335-2339.
157. Pin J.P., Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995, 34:1-26.
158. Pinheiro P.S., Mulle C. Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nat. Rev. Neurosci. 2008, 9:423-436.
159. Postina R., Schroeder A., Dewachter I., Bohl J., Schmitt U., Kojro E., Prinzen C., Endres K., Hiemke C., Blessing M., Flamez P., Dequenne A., Godaux E., van Leuven F., Fahrenholz F. Adisintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J.Clin. Invest. 2004, 113:1456-1464.
160. Pratico C., Quattrone D., Lucanto T., Amato A., Penna O., Roscitano C., Fodale V. Drugs of anesthesia acting on central cholinergic system may cause post-operative cognitive dysfunction and delirium. Med. Hypotheses 2005, 65:972-982.
161. Querfurth Henry W., LaFerla Frank M. Alzheimer's disease. New Engl. J. Med 2010.
162. Raber J., Huang Y., Ashford J.W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 2004, 25:641-650.
163. Raichle M.E., MacLeod A.M., Snyder A.Z., Powers W.J., Gusnard D.A., Shulman G.L. Adefault mode of brain function. Proc. Natl. Acad. Sci. U.S.A 2001, 98:676-682.
164. Rao V.R., Pintchovski S.A., Chin J., Peebles C.L., Mitra S., Finkbeiner S. AMPA receptors regulate transcription of the plasticity-related immediate-early gene Arc. Nat. Neurosci. 2006, 9:887-895.
165. Reynolds G.P., Mason S.L., Meldrum A., De Keczer S., Parnes H., Eglen R.M., Wong E.H. 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. Br. J. Pharmacol. 1995, 114:993-998.
166. Rhinn H., Fujita R., Qiang L., Cheng R., Lee J.H., Abeliovich A. Integrative genomics identifies APOE epsilon4 effectors in Alzheimer's disease. Nature 2013, 500:45-50.
167. Rissman R.A., De Blas A.L., Armstrong D.M. GABA(A) receptors in aging and Alzheimer's disease. J.Neurochem. 2007, 103:1285-1292.
168. Roberson E.D., Halabisky B., Yoo J.W., Yao J., Chin J., Yan F., Wu T., Hamto P., Devidze N., Yu G.-Q., Palop J.J., Noebels J.L., Mucke L. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J.Neurosci. 2011, 31:700-711.
169. Roberts G.W., Gentleman S.M., Lynch A., Graham D.I. beta A4 amyloid protein deposition in brain after head trauma. Lancet 1991, 338:1422-1423.
170. Rocca W.A., Amaducci L.A., Schoenberg B.S. Epidemiology of clinically diagnosed Alzheimer's disease. Ann. Neurol. 1986, 19:415-424.
171. Rodriguez J.J., Davies H.A., Silva A.T., De Souza I.E.J., Peddie C.J., Colyer F.M., Lancashire C.L., Fine A., Errington M.L., Bliss T.V.P., Stewart M.G. Long-term potentiation in the rat dentate gyrus is associated with enhanced Arc/Arg3.1 protein expression in spines, dendrites and glia. Eur. J. Neurosci. 2005, 21:2384-2396.
172. Roh J.H., Huang Y., Bero A.W., Kasten T., Stewart F.R., Bateman R.J., Holtzman D.M. Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Sci. Transl. Med. 2012, 4:150ra122.
173. Rossor M.N., Garrett N.J., Johnson A.L., Mountjoy C.Q., Roth M., Iversen L.L. Apost-mortem study of the cholinergic and GABA systems in senile dementia. Brain 1982, 105:313-330.
174. Rothman S.M., Olney J.W. Excitotoxicity and the NMDA receptor-still lethal after eight years. Trends Neurosci. 1995, 18:57-58.
175. Saido T.C., Yokota M., Maruyama K., Yamao-Harigaya W., Tani E., Ihara Y., Kawashima S. Spatial resolution of the primary beta-amyloidogenic process induced in postischemic hippocampus. J.Biol. Chem. 1994, 269:15253-15257.
176. Sakurai T., Mieda M., Tsujino N. The orexin system: roles in sleep/wake regulation. Ann. N. Y Acad. Sci. 2010, 1200:149-161.
177. Sanchez P.E., Zhu L., Verret L., Vossel K.A., Orr A.G., Cirrito J.R., Devidze N., Ho K., Yu G.Q., Palop J.J., Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc. Natl. Acad. Sci. U.S.A 2012, 109:E2895-E2903.
178. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J.Pharmacol. Exp. Ther. 2001, 299:12-20.
179. Schoepp D.D., Jane D.E., Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999, 38:1431-1476.
180. Selkoe D.J. Preventing Alzheimer's disease. Science 2012, 337:1488-1492.
181. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
182. Shen F., Smith J.A., Chang R., Bourdet D.L., Tsuruda P.R., Obedencio G.P., Beattie D.T. 5-HT(4) receptor agonist mediated enhancement of cognitive function invivo and amyloid precursor protein processing invitro: a pharmacodynamic and pharmacokinetic assessment. Neuropharmacology 2011, 61:69-79.
183. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K., Tsuda T., Mar L., Foncin J.F., Bruni A.C., Montesi M.P., Sorbi S., Rainero I., Pinessi L., Nee L., Chumakov I., Pollen D., Brookes A., Sanseau P., Polinsky R.J., Wasco W., Da Silva H.A., Haines J.L., Perkicak-Vance M.A., Tanzi R.E., Roses A.D., Fraser P.E., Rommens J.M., St George-Hyslop P.H. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995, 375:754-760.
184. Signore A.P., Zhang F., Weng Z., Gao Y., Chen J. Leptin neuroprotection in the CNS: mechanisms and therapeutic potentials. J.Neurochem. 2008, 106:1977-1990.
185. Sivilotti L., Nistri A. GABA receptor mechanisms in the central nervous system. Prog. Neurobiol. 1991, 36:35-92.
186. Skovronsky D.M., Moore D.B., Milla M.E., Doms R.W., Lee V.M. Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J.Biol. Chem. 2000, 275:2568-2575.
187. Smith D.H., Nakamura M., McIntosh T.K., Wang J., Rodriguez A., Chen X.H., Raghupathi R., Saatman K.E., Clemens J., Schmidt M.L., Lee V.M., Trojanowski J.Q. Brain trauma induces massive hippocampal neuron death linked to a surge in beta-amyloid levels in mice overexpressing mutant amyloid precursor protein. Am. J. Pathol. 1998, 153:1005-1010.
188. Sparks D.L., Hunsaker J.C., Scheff S.W., Kryscio R.J., Henson J.L., Markesbery W.R. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol. Aging 1990, 11:601-607.
189. Steward O., Worley P.F. Selective targeting of newly synthesized Arc mRNA to active synapses requires NMDA receptor activation. Neuron 2001, 30:227-240.
190. Stranahan A.M., Arumugam T.V., Cutler R.G., Lee K., Egan J.M., Mattson M.P. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat. Neurosci. 2008, 11:309-317.
191. Suberbielle E., Sanchez P.E., Kravitz A.V., Wang X., Ho K., Eilertson K., Devidze N., Kreitzer A.C., Mucke L. Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-beta. Nat. Neurosci. 2013, 16:613-621.
192. Sun X., Meng X., Zhang J., Li Y., Wang L., Qin X., Sui N., Zhang Y. GABA attenuates amyloid toxicity by downregulating its endocytosis and improves cognitive impairment. J.Alzheimers Dis. 2012, 31:635-649.
193. Tampellini D., Gouras G.K. Synapses, synaptic activity and intraneuronal abeta in Alzheimer's disease. Front Aging Neurosci. 2010, 2.
194. Tan K.S., Nackley A.G., Satterfield K., Maixner W., Diatchenko L., Flood P.M. Beta2 adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA- and NF-kappaB-independent mechanisms. Cell Signal 2007, 19:251-260.
195. Teber I., Kohling R., Speckmann E.-J., Barnekow A., Kremerskothen J. Muscarinic acetylcholine receptor stimulation induces expression of the activity-regulated cytoskeleton-associated gene (ARC). Brain Res. Mol. Brain Res. 2004, 121:131-136.
196. Teter B., Ashford J.W. Neuroplasticity in Alzheimer's disease. J.Neurosci. Res. 2002, 70:402-437.
197. Thathiah A., Horre K., Snellinx A., Vandewyer E., Huang Y., Ciesielska M., De Kloe G., Munck S., De Strooper B. beta-arrestin 2 regulates abeta generation and gamma-secretase activity in Alzheimer's disease. Nat. Med. 2013, 19:43-49.
198. Tomozawa Y., Yabuuchi K., Inoue T., Satoh M. Participation of cAMP and cAMP-dependent protein kinase in beta-adrenoceptor-mediated interleukin-1 beta mRNA induction in cultured microglia. Neurosci. Res. 1995, 22:399-409.
199. Tucker S., Ahl M., Cho H.H., Bandyopadhyay S., Cuny G.D., Bush A.I., Goldstein L.E., Westaway D., Huang X., Rogers J.T. RNA therapeutics directed to the non coding regions of APP mRNA, invivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. Curr. Alzheimer Res. 2006, 3:221-227.
200. Turrigiano G.G., Nelson S.B. Homeostatic plasticity in the developing nervous system. Nat. Rev. Neurosci. 2004, 5:97-107.
201. Ulrich J., Johannson-Locher G., Seiler W.O., Stahelin H.B. Does smoking protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. Acta Neuropathol. 1997, 94:450-454.
202. Verret L., Mann E.O., Hang G.B., Barth A.M., Cobos I., Ho K., Devidze N., Masliah E., Kreitzer A.C., Mody I., Mucke L., Palop J.J. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 2012, 149:708-721.
203. Vyazovskiy V.V., Cirelli C., Pfister-Genskow M., Faraguna U., Tononi G. Molecular and electrophysiological evidence for net synaptic potentiation in wake and depression in sleep. Nat. Neurosci. 2008, 11:200-208.
204. Walsh D.M., Klyubin I., Shankar G.M., Townsend M., Fadeeva J.V., Betts V., Podlisny M.B., Cleary J.P., Ashe K.H., Rowan M.J., Selkoe D.J. The role of cell-derived oligomers of abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem. Soc. Trans. 2005, 33:1087-1090.
205. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
206. Wang D.C., Chen S.S., Lee Y.C., Chen T.J. Amyloid-beta at sublethal level impairs BDNF-induced arc expression in cortical neurons. Neurosci. Lett. 2006, 398:78-82.
207. Wasco W., Bupp K., Magendantz M., Gusella J.F., Tanzi R.E., Solomon F. Identification of a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid beta protein precursor. Proc. Natl. Acad. Sci. U.S.A 1992, 89:10758-10762.
208. Wasco W., Gurubhagavatula S., Paradis M.D., Romano D.M., Sisodia S.S., Hyman B.T., Neve R.L., Tanzi R.E. Isolation and characterization of APLP2 encoding a homologue of the Alzheimer's associated amyloid beta protein precursor. Nat. Genet. 1993, 5:95-100.
209. Waung M.W., Pfeiffer B.E., Nosyreva E.D., Ronesi J.A., Huber K.M. Rapid translation of Arc/Arg3.1 selectively mediates mGluR-dependent LTD through persistent increases in AMPAR endocytosis rate. Neuron 2008, 59:84-97.
210. Wayner M.J., Armstrong D.L., Phelix C.F., Oomura Y. Orexin-A (Hypocretin-1) and leptin enhance LTP in the dentate gyrus of rats invivo. Peptides 2004, 25:991-996.
211. Wegenast-Braun B.M., Fulgencio Maisch A., Eicke D., Radde R., Herzig M.C., Staufenbiel M., Jucker M., Calhoun M.E. Independent effects of intra- and extracellular abeta on learning-related gene expression. Am. J. Pathol. 2009, 175:271-282.
212. Wu J., Petralia R.S., Kurushima H., Patel H., Jung M.Y., Volk L., Chowdhury S., Shepherd J.D., Dehoff M., Li Y., Kuhl D., Huganir R.L., Price D.L., Scannevin R., Troncoso J.C., Wong P.C., Worley P.F. Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent beta-amyloid generation. Cell 2011, 147:615-628.
213. Xie L., Kang H., Xu Q., Chen M.J., Liao Y., Thiyagarajan M., O'Donnell J., Christensen D.J., Nicholson C., Iliff J.J., Takano T., Deane R., Nedergaard M. Sleep drives metabolite clearance from the adult brain. Science 2013, 342:373-377.
214. Ying S.-W., Futter M., Rosenblum K., Webber M.J., Hunt S.P., Bliss T.V.P., Bramham C.R. Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. J.Neurosci. 2002, 22:1532-1540.
215. Yoshida Y., Fujiki N., Nakajima T., Ripley B., Matsumura H., Yoneda H., Mignot E., Nishino S. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur. J. Neurosci. 2001, 14:1075-1081.
216. Younkin S.G. The role of Abeta 42 in Alzheimer's disease. J.Physiol. Paris 1998, 92:289-292.
217. Yu J.T., Tan L., Ou J.R., Zhu J.X., Liu K., Song J.H., Sun Y.P. Polymorphisms at the beta2-adrenergic receptor gene influence Alzheimer's disease susceptibility. Brain Res. 2008, 1210:216-222.
218. Yu K., Ge S.-Y., Ruan D.-Y. Fe2+ decreases the taurine-induced Cl- current in acutely dissociated rat hippocampal neurons. Brain Res. 2003, 960:25-35.
219. Zou K., Kim D., Kakio A., Byun K., Gong J.S., Kim J., Kim M., Sawamura N., Nishimoto S., Matsuzaki K., Lee B., Yanagisawa K., Michikawa M. Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by abeta1-42 in culture and in rat brain. J.Neurochem. 2003, 87:609-619.